Biotech Patents: Equivalency and Exclusions Under European and U.S. Patent Law

Product DescriptionThere is no denying that biotechnological inventions in some ways have challenged the legal system of providing market exclusivity through patents. First of all, their patentability has been questioned. Furthermore, the scope of protection conferred to these inventions is obscured because of the difficulty of applying legal concepts to [...]

OSI Pharmaceuticals Announces That Tarceva® Received Approval in the European Union for Maintenance Use in Advanced …

OSI Pharmaceuticals Announces That Tarceva® Received Approval in the European Union for Maintenance Use in Advanced …
MELVILLE, N.Y.—-OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® , Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer whose disease remains largely [...]

OSI Pharmaceuticals announces European Commission’s approval of Tarceva for NSCLC

OSI Pharmaceuticals announces European Commission’s approval of Tarceva for NSCLC
OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.
Read [...]

Medpace Inc. Expands Therapeutic Capabilities With the Acquisition of Pharma Brains AG, a European CRO With Global Experience in Oncology Drug Develop

CINCINNATI, OH–(Marketwire – November 2, 2009) – Medpace, a privately held, global full-service clinical research organization, today announced it has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.
Pharma Brains is an excellent fit with Medpace in terms of its complementary therapeutic expertise, strong leadership and [...]

Medpace, Inc. Continues Their European Expansion With the Acquisition of Medical Consulting Dr. Schlichtiger GmbH, a European CRO With Key Expertise i

CINCINNATI, OH–(Marketwire – January 18, 2010) – Medpace, a privately held, global, full-service clinical research organization, is pleased to announce that it has acquired Medical Consulting Dr. Schlichtiger GmbH, a European CRO with extensive drug development expertise providing customized regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies of all sizes based in Munich, [...]

Next Page »